Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KZR |
---|---|---|
09:32 ET | 3011 | 0.64 |
09:38 ET | 1200 | 0.6346 |
09:39 ET | 520 | 0.6301 |
09:41 ET | 501 | 0.6301 |
09:48 ET | 15293 | 0.6305 |
09:52 ET | 200 | 0.6324 |
09:54 ET | 300 | 0.6343 |
09:56 ET | 400 | 0.6343 |
09:57 ET | 300 | 0.6343 |
09:59 ET | 355 | 0.6324 |
10:01 ET | 9700 | 0.6328 |
10:03 ET | 5550 | 0.634299 |
10:06 ET | 1700 | 0.6444 |
10:08 ET | 1400 | 0.64205 |
10:10 ET | 100 | 0.64 |
10:12 ET | 3500 | 0.6339 |
10:14 ET | 400 | 0.6339 |
10:17 ET | 13213 | 0.6384 |
10:19 ET | 600 | 0.64 |
10:21 ET | 500 | 0.64 |
10:24 ET | 15600 | 0.64035 |
10:26 ET | 800 | 0.6403 |
10:28 ET | 1100 | 0.6381 |
10:30 ET | 800 | 0.6381 |
10:32 ET | 1600 | 0.6381 |
10:33 ET | 1800 | 0.6399 |
10:35 ET | 1600 | 0.6381 |
10:37 ET | 500 | 0.6381 |
10:39 ET | 700 | 0.6401 |
10:42 ET | 500 | 0.6401 |
10:44 ET | 900 | 0.6381 |
10:46 ET | 300 | 0.64005 |
10:48 ET | 670 | 0.64 |
10:50 ET | 1504 | 0.6383 |
10:51 ET | 200 | 0.6401 |
10:53 ET | 600 | 0.6383 |
10:55 ET | 200 | 0.64015 |
11:00 ET | 800 | 0.6401 |
11:02 ET | 523 | 0.6383 |
11:04 ET | 2830 | 0.6382 |
11:06 ET | 700 | 0.6407 |
11:08 ET | 753 | 0.6382 |
11:09 ET | 13799 | 0.634 |
11:11 ET | 400 | 0.63715 |
11:13 ET | 400 | 0.634 |
11:15 ET | 700 | 0.634 |
11:18 ET | 700 | 0.634 |
11:20 ET | 1400 | 0.63715 |
11:22 ET | 1000 | 0.6342 |
11:24 ET | 1200 | 0.6342 |
11:26 ET | 800 | 0.6372 |
11:27 ET | 415 | 0.6372 |
11:29 ET | 867 | 0.6373 |
11:31 ET | 1128 | 0.6346 |
11:33 ET | 1200 | 0.6374 |
11:36 ET | 757 | 0.6374 |
11:38 ET | 1000 | 0.6346 |
11:40 ET | 570 | 0.6374 |
11:42 ET | 305 | 0.6346 |
11:44 ET | 432 | 0.6401 |
11:45 ET | 200 | 0.6346 |
11:47 ET | 700 | 0.6347 |
11:49 ET | 26481 | 0.63 |
11:51 ET | 26989 | 0.6293 |
11:54 ET | 1700 | 0.623 |
11:56 ET | 31921 | 0.6233 |
11:58 ET | 1400 | 0.6233 |
12:00 ET | 17933 | 0.62495 |
12:02 ET | 28771 | 0.62745 |
12:03 ET | 2100 | 0.6274 |
12:05 ET | 14537 | 0.62 |
12:07 ET | 3300 | 0.62 |
12:09 ET | 1930 | 0.6223 |
12:12 ET | 4891 | 0.6226 |
12:14 ET | 1696 | 0.6252 |
12:16 ET | 1140 | 0.6211 |
12:18 ET | 15606 | 0.6147 |
12:20 ET | 8820 | 0.6116 |
12:21 ET | 3987 | 0.6137 |
12:23 ET | 3609 | 0.6234 |
12:25 ET | 668 | 0.6223 |
12:27 ET | 2970 | 0.62235 |
12:30 ET | 2386 | 0.6246 |
12:32 ET | 1143 | 0.6234 |
12:34 ET | 1663 | 0.6234 |
12:36 ET | 4029 | 0.6245 |
12:38 ET | 2247 | 0.6246 |
12:39 ET | 2085 | 0.6245 |
12:41 ET | 2558 | 0.6231 |
12:43 ET | 1887 | 0.6246 |
12:45 ET | 2832 | 0.624 |
12:48 ET | 4280 | 0.6234 |
12:50 ET | 2165 | 0.6234 |
12:52 ET | 2052 | 0.624 |
12:54 ET | 2248 | 0.624 |
12:56 ET | 39607 | 0.6234 |
12:57 ET | 2291 | 0.623 |
12:59 ET | 1484 | 0.6223 |
01:01 ET | 3400 | 0.62155 |
01:03 ET | 6482 | 0.6223 |
01:06 ET | 3664 | 0.62 |
01:08 ET | 45186 | 0.621851 |
01:10 ET | 27086 | 0.6095 |
01:12 ET | 26569 | 0.61 |
01:14 ET | 24878 | 0.61 |
01:15 ET | 11618 | 0.606 |
01:17 ET | 8091 | 0.6013 |
01:19 ET | 112973 | 0.5981 |
01:21 ET | 13411 | 0.5992 |
01:24 ET | 4643 | 0.60265 |
01:26 ET | 5661 | 0.60265 |
01:28 ET | 5240 | 0.61 |
01:30 ET | 1350 | 0.60795 |
01:32 ET | 4822 | 0.6088 |
01:33 ET | 3246 | 0.60895 |
01:35 ET | 2000 | 0.6079 |
01:37 ET | 2847 | 0.6091 |
01:39 ET | 3507 | 0.6095 |
01:42 ET | 4505 | 0.6061 |
01:44 ET | 200 | 0.6056 |
01:46 ET | 2207 | 0.603 |
01:48 ET | 11708 | 0.60375 |
01:50 ET | 3502 | 0.60395 |
01:51 ET | 4597 | 0.6043 |
01:53 ET | 2887 | 0.6042 |
01:55 ET | 28626 | 0.61 |
01:57 ET | 4332 | 0.61 |
02:00 ET | 30237 | 0.6093 |
02:02 ET | 9816 | 0.6086 |
02:04 ET | 1320 | 0.6081 |
02:06 ET | 2100 | 0.6086 |
02:08 ET | 656 | 0.6083 |
02:09 ET | 4553 | 0.6083 |
02:11 ET | 9644 | 0.6107 |
02:13 ET | 16765 | 0.6142 |
02:15 ET | 10002 | 0.6147 |
02:18 ET | 802 | 0.6137 |
02:20 ET | 2153 | 0.6137 |
02:22 ET | 3466 | 0.6143 |
02:24 ET | 2964 | 0.61395 |
02:26 ET | 13932 | 0.6143 |
02:27 ET | 890 | 0.6135 |
02:29 ET | 2772 | 0.6144 |
02:31 ET | 2804 | 0.6136 |
02:33 ET | 1592 | 0.6142 |
02:36 ET | 1919 | 0.61425 |
02:38 ET | 1800 | 0.61425 |
02:40 ET | 2905 | 0.6144 |
02:42 ET | 1826 | 0.6143 |
02:44 ET | 794 | 0.6142 |
02:45 ET | 2621 | 0.6141 |
02:47 ET | 3285 | 0.61425 |
02:49 ET | 1160 | 0.6138 |
02:51 ET | 1700 | 0.6128 |
02:54 ET | 1887 | 0.6106 |
02:56 ET | 1339 | 0.6107 |
02:58 ET | 3825 | 0.6118 |
03:00 ET | 18956 | 0.6118 |
03:02 ET | 3235 | 0.6123 |
03:03 ET | 2508 | 0.6126 |
03:05 ET | 1684 | 0.6136 |
03:07 ET | 8481 | 0.6158 |
03:09 ET | 2830 | 0.6158 |
03:12 ET | 1524 | 0.61575 |
03:14 ET | 1593 | 0.6178 |
03:16 ET | 1492 | 0.61605 |
03:18 ET | 2324 | 0.618 |
03:20 ET | 3647 | 0.6159 |
03:21 ET | 3355 | 0.6155 |
03:23 ET | 2133 | 0.6155 |
03:25 ET | 13841 | 0.61465 |
03:27 ET | 7901 | 0.6144 |
03:30 ET | 5818 | 0.6144 |
03:32 ET | 10331 | 0.61555 |
03:34 ET | 2298 | 0.6152 |
03:36 ET | 3425 | 0.6158 |
03:38 ET | 52326 | 0.6202 |
03:39 ET | 24246 | 0.61475 |
03:41 ET | 37338 | 0.6129 |
03:43 ET | 5576 | 0.6114 |
03:45 ET | 25489 | 0.6072 |
03:48 ET | 46132 | 0.6104 |
03:50 ET | 6097 | 0.6104 |
03:52 ET | 12077 | 0.6104 |
03:54 ET | 24257 | 0.6165 |
03:56 ET | 14594 | 0.616 |
03:57 ET | 43983 | 0.622 |
03:59 ET | 55784 | 0.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kezar Life Sciences Inc | 43.7M | -0.4x | --- |
LAVA Therapeutics NV | 47.3M | -1.7x | --- |
Atara Biotherapeutics Inc | 41.7M | -0.2x | --- |
DURECT Corp | 40.0M | -1.5x | --- |
BioLine RX Ltd | 48.9M | -0.7x | --- |
Evogene Ltd | 32.9M | -1.4x | --- |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.7M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.27 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.